No patient should have to face the threat of rabies. That's why a patient assistance program is available to ensure uninsured patients have access to HyperRAB.
HyperRAB® (rabies immune globulin [human])
The only human rabies immunoglobulin (HRIG) with a higher-potency formulation, offering potentially fewer injections in administration of each dose.
Use the only HRIG that offers
HyperRAB is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.
Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.
For unvaccinated persons, the combination of HyperRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.
Trust more than 40 years of leadership. HyperRAB1,2:
- Mercury (thimerosal), latex, and preservative free
- Food and Drug Administration (FDA) labeling for capacity to remove pathogenic prions
- Low procoagulant activity
- Low levels of IgG aggregates
- Tamper-evident packaging
Postexposure Prophylaxis (PEP) for Rabies
More than 60,000 people report coming in contact with potentially rabid animals and receive rabies PEP each year.1
Be sure to follow the CDC PEP schedule4
For more information, recommendations, and guidelines, visit the CDC Advisory Committee on Immunization Practices (ACIP).
Imminent Threat, Immediate Protection
Vaccines can take weeks to build efficacy, but HyperRAB provides immediate protection. This allows the vaccine the time needed to establish active immunity, giving your patients the critical protection they need now.5
Caprylate function within the caprylate/chromatography purification process
- Caprylate is a naturally occurring octanoic fatty acid that facilitates precipitation of impurities and provides an effective capacity to remove/inactivate viruses in case of contamination7,8
- Immunoglobulin G (IgG) remains soluble and stable during processing, which minimizes loss of functionality8
- Protein purification is achieved by sequential passage through anion exchange chromatographic columns8
- 5 steps with capacity to remove/inactivate viruses including emerging viruses (e.g., West Nile virus)9
- FDA labeling for capacity to remove pathogenic prions2
- Since the implementation of sensitive serological screening tests over 30 years ago10-12
- No confirmed case of virus transmission by IgG products for intramuscular injection
- No case of prion transmission, including human form bovine spongiform encephalopathy
HyperRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Only HyperRAB, at twice the potency of currently available HRIG options, offers the benefit of potentially fewer injections in administration of each dose
The recommended dose for HyperRAB is 20 IU/kg or 0.0665 mL/kg of body weight given at time of first vaccine dose. HyperRAB may also be given up to the eighth day after the first dose of vaccine. Do not exceed the recommended dose, as this could partially suppress active production of rabies antibody.2
HyperRAB® (rabies immune globulin [human]) 300 IU/mL
Enter your patients weight to determine their HyperRAB dose.*
DOSE NEEDED (IU)
DOSE NEEDED (mL)
NUMBER OF VIALS†